- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)
- Meeting Date: May 2025
- Public Summary Document (PSD) May 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) May 2025 PBAC Meeting - (Word)
Nirsevimab – May 2025
Nirsevimab: Solution for injection 50 mg in 0.5 mL pre-filled syringe, Solution for injection 100 mg in 1 mL pre-filled syringe; Beyfortus®
Last updated
5 May 2025